IBI188
Sponsors
Innovent Biologics (Suzhou) Co. Ltd.
Conditions
Acute Myeloid LeukemiaAdvanced MalignanciesLung AdenocarcinomaMDSOsteosarcomaSolid Tumors
Phase 1
A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies
CompletedNCT03717103
Start: 2019-01-10End: 2022-02-16Updated: 2022-04-07
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
CompletedNCT03763149
Start: 2019-02-19End: 2021-03-29Updated: 2021-12-06
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
SuspendedNCT04485052
Start: 2020-09-25End: 2024-12-31Target: 222Updated: 2023-10-23
A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS
SuspendedNCT04511975
Start: 2020-08-24End: 2022-04-04Target: 32Updated: 2020-12-21
IBI188 Combination Therapy in Solid Tumors
TerminatedNCT04861948
Start: 2021-05-25End: 2022-07-30Updated: 2022-10-04